The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...

Swedish biotech Anocca has raised about 440 million Swedish kronor ($46 million) in new financing to accelerate development ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Swedish biotechnology company Anocca has secured approximately Skr440m ($46m) to primarily support the early-stage clinical ...

Mutations in the GTPase KRAS drive proliferation of many types of tumors, and daraxonrasib (RMC-6236), which inhibits various KRAS mutants, can slow growth of pancreatic and lung cancers. Researchers ...

Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...